Specifically, Biofield has acquired the exclusive worldwide distribution rights outside of Belgium, for ValiRx’s human papilloma virus diagnostic test for cervical cancer as well as for ValiRx’s HyperGenomics and Nucleosomic cancer diagnostics products.
The company is currently focusing on distributing its product portfolio in China (including Hong Kong, Taiwan and Macau), India, the Philippines, Indonesia, Malaysia, Singapore, Vietnam, and other parts of Asia, Mexico, Latin America and Europe.
The company has also opened an office in Bangalore, India where it is has been preparing to begin marketing the oral herpes device pursuant to the exclusive worldwide distribution rights it acquired from NeuroMed, as previously announced. The company expects to begin marketing the device through a wholly owned Indian subsidiary, via direct web based/internet marketing, retail, wholesale and through physicians and hospitals within the next 30 days.
Shepard Bentley, CEO of Biofield, said: We are very pleased to be able to add a human papilloma virus diagnostic test for cervical cancer as well as ValioRx’s HyperGenomics and Nucleosomics cancer diagnostics products to our portfolio.